Association of polymorphisms in glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) with idiopathic azoospermia or oligospermia in Sichuan, China

Da-Ke Xiong1,2,3*, Hong-Han Chen1,2,3*, Xian-Ping Ding1,2,3, Shao-Hong Zhang1,2,3, Jian-Hui Zhang1,2,3

The reported effects of the glutathione S-transferase (GSTs) genes (GSTM1, GSTT1, and GSTP1) on male factor infertility have been inconsistent and even contradictory. Here, we conducted a case-control study to investigate the association between functionally important polymorphisms in GST genes and idiopathic male infertility. The study group consisted of 361 men with idiopathic azoospermia, 118 men with idiopathic oligospermia, and 234 age-matched healthy fertile male controls. Genomic DNA was extracted from the peripheral blood, and analyzed by polymerase chain reaction and restriction fragment length polymorphism analysis. There was a significant association between the GSTP1 variant genotype (Ile/Val + Val/Val) with idiopathic infertility risk (odds ratio [OR]: 1.53; 95% confidence interval [CI]: 1.11–2.11; P = 0.009). Similarly, a higher risk of infertility was noted in individuals carrying a genotype combination of GSTT1-null and GSTP1 (Ile/Val + Val/Val) (OR: 2.17; 95% CI: 1.43–3.31; P = 0.0002). These results suggest an increased risk of the GSTP1 variant genotype (Ile/Val + Val/Val) for developing male factor infertility. Our findings also underscore the significance of the effect of GSTM1 and/or GSTT1 (especially the former) in modulating the risk of male infertility in males from Sichuan, southwest China.

Asian Journal of Andrology (2015) 17, 481–486; doi: 10.4103/1008-682X.143737; published online: 05 December 2014

Keywords: genetic polymorphism; glutathione S-transferase; idiopathic infertility; male factor

INTRODUCTION
Infertility is a worldwide reproductive health problem affecting approximately 12%–15% of couples.1 In about half of the cases, poor semen quality is a major cause.2,3 Male infertility represents a typical example of complex disease with a substantial genetic basis.4 The etiology and pathogenesis remain unknown in about 30% of male cases of infertility; this is termed “idiopathic infertility.”5 Over the past two decades, the quantity and quality of human semen have declined,6 which has raised global concerns about male fertility.

Male germ cells are highly susceptible to stress;7 therefore, an important way to ensure fertility is protection from oxidative stress. Glutathione S-transferases (GSTs; EC 2.5.1.18) belong to a superfamily of ubiquitous, multifunctional dimeric cystolic enzymes that play a key role in the Phase II detoxification pathways in humans against various physiological and xenobiotic substances by catalyzing the conjugation of the nucleophilic tripeptide glutathione to a wide range of electrophilic substrates.8 Hence, GSTs constitute the major defensive antioxidant system against oxidative stress by reducing reactive oxygen species, which are generated by many toxic xenobiotics.9 In human, GSTs consist of many cytosolic, mitochondrial, and microsomal proteins. The cystolic family has been categorized into eight separate classes – α (alpha), μ (mu), κ (kappa), π (pi), σ (sigma), θ (theta), and ζ (zeta) – encoded by the GSTA, GSTM, GSTK, GSTO, GSTP, GSTS, GSTT, and GSTZ genes, respectively.10 Each class includes several genes and isoenzymes.10 Functional polymorphisms have mainly been reported in the GSTM1, GSTT1, and GSTP1 genes.11-14

In India, Tirumala Vani et al.15 identified an association between the GSTM1 null genotype and idiopathic male infertility. In the United States of America, Olshan et al.15 reported that the GSTT1 nonnull genotype was associated with reduced sperm concentration and count in semen. In Iran, Safarinejad et al.16 revealed an increased risk of the GSTM1 and/or GSTT1 null genotypes for developing infertility with a protective effect conferred by the variant genotypes of GSTP1.

In China, Wu et al.17 found that the GSTT1 null genotype was a predisposing risk factor for sporadic idiopathic azoospermia or oligospermia. Tang et al.17 revealed that GSTM1 and GSTT1 null genotypes may predispose sperm to increased oxidative damage in infertile men with varicoceles, while GSTP1 allelic variation was associated with no difference between cases and controls.

Despite the intriguing results of the two abovementioned studies, there are few reports in China on the association between GSTs and idiopathic infertility. Therefore, we designed this case-control study to
assess the risk of idiopathic male infertility associated with GSTM1, GSTT1, and GSTP1 in Sichuan, China.

MATERIALS AND METHODS

Subjects

We carried out a case-control study of 479 male partners of infertile couples who showed an abnormal spermiogram (361 with nonobstructive azoospermia and 118 with oligospermia) and attended the Affiliate Hospital of Sichuan Genitalia Hygiene Research Center (Chengdu, Sichuan, China), from July 2010 to May 2013. All the men had an infertility history of at least 2 years with no indication of hormonal, medical, or surgical causes for their infertility; their spouses had a normal gynecological assessment. Exclusion criteria included a history of epididymo-orchitis, prostatitis, genital trauma and testicular tumors; genital disease such as cryptorchidism, congenital bilateral absence of the vas deferens or varicocele; seminal infections; diabetes; Y chromosome microdeletions, cytogenetic, or karyotype abnormalities; drug, alcohol, or substance abuse; and tobacco use. Semen analysis was performed according to World Health Organization recommendations. Two hundred thirty-four fertile men of a comparable age who had fathered at least one child without assisted reproductive technologies were selected for the control group. All participants were informed about the study according to a protocol that was approved by the Institutional Ethical Review boards of Sichuan University (Chengdu, China), and all gave their written consent.

Genotyping

Genomic DNA was extracted from peripheral venous blood using an Ezup Column Blood Genomic DNA Purification Kit (Sangon Biotech, Shanghai, China) according to the manufacturer’s instructions. Spectroscopy was performed to quantify the amount of extracted genomic DNA. DNA samples were stored at −20°C.

Multiplex polymerase chain reaction (PCR) was performed to detect the GSTM1 and GSTT1 genotypes in a total volume of 25 μl buffer solution containing approximately 100 ng genomic DNA, 0.2 mmol l−1 dNTPs (TransGen, Beijing, China), 1.5 mmol l−1 Mg2+ (Fermentas International Inc., Burlington, ON, Canada), 4 × 105 pmol l−1 of each primer (Sangon Biotech, Shanghai, China) and 1 U Taq polymerase (Fermentas International Inc., Burlington, ON, Canada). The reaction mixture was heated at 95°C for 5 min, followed by 35 cycles of amplification as follows: a denaturing step at 94°C for 30 s, an annealing step at 60°C for 30 s, and an extension step at 72°C for 45 s. The final extension was at 72°C for 10 min. PCR samples were analyzed on a 2% agarose gel prepared in 1 × TAE buffer containing DuRed nucleic acid gel stain (Abgent Biotechnology Co., Ltd., Suzhou, China) run at 110 V for 40 min at room temperature (Figure 1b).

Homozgyous Ile/Ile individuals showed two fragments, of 328 bp and 105 bp. Homozgyous Val/Val individuals also showed two bands (three fragments of 222 bp, 106 bp, and 105 bp; the latter two merged into one band). The presence of all three bands corresponded to heterozygous Ile/Val individuals. A random selection of 15% of Ile/Ile and Ile/Val samples, plus all the Val/Val samples, were retested by sequencing by Sangon Biotech (Figure 2); no discrepancies were found.

Statistical analysis

The χ2 test was performed to compare genotype frequencies between groups. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated to measure the risk associated with variant genotypes using the unconditional logistic regression method. Tests for Hardy–Weinberg equilibrium were also conducted by the χ2 test. P < 0.05 was considered statistically significant. The data were analyzed using Statistical Package for Social Sciences software version 20.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Demographic and clinical characteristics of the subjects

Semen parameters in each study group are shown in Table 1. Mean age (± s.d.) was 30.8 ± 5.2 years among men with azoospermia (age range 25–40 years), 30.7 ± 5.5 years among men with oligospermia (age range 24–40 years), and 32.8 ± 5.7 years among controls (age range 25–42 years). No significant differences were observed between cases and controls with respect to age.

Figure 1: Primers for the GSTM1 gene were: 5′-CTGCCCTAATCTTATGATGAGG-3′ and 5′-CTGGATTGAGATGAGCAGC-3′; those for GSTT1 were: 5′-CTCCTAATCTTATGAGCAGC-3′ and 5′-TCACGGATCATGACCCAG-3′; primers for human β-globin (110-bp amplicon), used as an internal control, were: 5′-ACACAACTGTGGTTACTAGC-3′ and 5′-CAACTGTGGTTACTAGC-3′. All primers were manufactured by Sangon Biotech. (a) Detection of the GSTM1 and GSTT1 alleles by multiplex polymerase chain reaction. M: 100 bp DNA ladder (Sangon Biotech, Shanghai, China); lanes 3, 4, 11, 12, 14: Even internal control is missing, these are to be retested; lane 5, 16: GSTM1 present and GSTT1 present; lanes 6, 10: GSTT1 present; lanes 1, 2, 7–9, 15: GSTM1 present; lane 13: GSTM1 null and GSTT1 null. (b) Detection of GSTP1 by restriction fragment length polymorphism. M: DL 1,000 DNA Marker (Takara Biotechnology Co., Ltd., Dalian, China); lanes 1, 5, 9, 11, 16–18, 23, 24: GSTP1 (Ile/Val); lanes 2–4, 6–8, 10, 13–15, 20, 22, 25: GSTP1 (Ile/Ile); lanes 12, 19, 21: GSTP1 (Val/Val).
Association of single gene polymorphisms with male infertility

The frequency of the GSTM1 null genotype showed almost no difference between the infertile men (51.6%) and the fertile controls (50.9%). Similarly, the GSTT1 null genotype was not more prevalent in the infertile men (52.0%) compared with 47.0% in controls. However, it was found to be more prevalent in people with oligospermia (OR: 1.59; 95% CI: 1.02–2.48; \( P = 0.043 \)). The frequency of the Ile/Ile genotype (the wild-type) of GSTP1 was found to be higher in controls (62.4%) than in the infertile men (52.0%). Because the frequency of the homozygous mutant (Val/Val) genotype of GSTP1 was very rare in both the infertile cases (1.9%) and the controls (2.1%), the heterozygous and homozygous mutant genotypes were combined (Ile/Val + Val/Val) and are referred to as variant genotypes of GSTP1. The frequency of variant GSTP1 was higher in cases (48.0%) than in controls (37.6%), showing a significant increased risk for infertility (OR: 1.53; 95% CI: 1.11–2.11; \( P = 0.009 \)) (Table 2).

Association of double gene combined polymorphisms with male infertility

When the genotypes of GSTM1 and GSTT1 were combined, three genetic combinations were studied: (1) both genotypes present; (2) either GSTM1- or GSTT1-present; and (3) both genotypes null. There was no significant association between the genotype combinations and infertility.

When combinations of GSTM1 and GSTP1 were studied, the frequency of the GSTM1-present and GSTP1-variant genotype was 114/479 (23.8%), which was higher than that in control subjects (42/234, 17.9%). Similarly, 28.8% of the people with idiopathic oligospermia and 19.7% of controls carried the combination genotype of GSTM1-null and GSTP1-variant. However, neither reached statistical significance.

Approximately 26% of the infertile people and 14% of the controls carried the combination genotype of GSTT1-null and GSTP1-variant,

**Table 1: Age and semen parameters of the study groups**

|                | Azoospermia (n=361) | Oligospermia (n=118) | Controls (n=234) |
|----------------|----------------------|----------------------|------------------|
| Age (year)     | 30.8±5.2             | 30.7±5.5             | 32.8±5.7         |
| Ejaculate volume (ml) | -                    | 3.4±1.7             | 3.5±1.6         |
| Total sperm/ejaculate | -                    | 31.3±14.0           | 135.9±58.7      |
| Sperm density  | -                    | 12.1±5.4            | 52.6±22.7       |
| Motility       | -                    | 27.9±13.0           | 36.6±10.3       |

The data are expressed as mean±s.d.; s.d.: standard deviation

**Table 2: Distribution of GSTM1, GSTT1, and GSTP1 genotypes among infertile males and controls**

| Genotype and allele frequency | Controls (n=234) | Azoospermia (n=361) | Oligospermia (n=118) | All cases (n=479) |
|------------------------------|------------------|----------------------|----------------------|-------------------|
| **GSTM1**                    |                  |                      |                      |                   |
| Present                      | n (%)            | 115 (49.1%)          | 172 (47.6%)          | 60 (50.8%)        |
| Null                         | n (%)            | 119 (50.9%)          | 189 (52.3%)          | 58 (49.1%)        |
| Odds ratio (95% CI)          |                  | 1.06 (0.76–1.48)     | 0.93 (0.60–1.45)     | 1.03 (0.75–1.40)  |
| P                            |                  | 0.721                | 0.763                | 0.859             |
| **GSTT1**                    |                  |                      |                      |                   |
| Present                      | n (%)            | 124 (53.0%)          | 181 (50.1%)          | 49 (41.5%)        |
| Null                         | n (%)            | 110 (47.0%)          | 180 (49.9%)          | 69 (58.5%)        |
| Odds ratio (95% CI)          |                  | 1.12 (0.80–1.56)     | 1.59 (1.02–2.48)     | 1.22 (0.89–1.67)  |
| P                            |                  | 0.497                | 0.043*               | 0.213             |
| **GSTP1**                    |                  |                      |                      |                   |
| Ile/Ile                      | n (%)            | 146 (62.4%)          | 191 (52.9%)          | 58 (49.2%)        |
| Odds ratio (95% CI)          |                  | 1.48 (1.06–2.08)     | 1.82 (1.16–2.85)     | 1.56 (1.13–2.15)  |
| P                            |                  | 0.023*               | 0.009*               | 0.007*            |
| Val/Val                      | n (%)            | 8 (2.1%)             | 8 (2.2%)             | 1 (0.8%)          |
| Odds ratio (95% CI)          |                  | 1.04 (0.34–3.21)     | 0.39 (0.04–3.39)     | 0.88 (0.29–2.65)  |
| P                            |                  | 0.948                | 0.378                | 0.816             |
| Ile/Val and Val/Val          | n (%)            | 88 (37.6%)           | 170 (47.1%)          | 60 (50.8%)        |
| Odds ratio (95% CI)          |                  | 1.48 (1.06–2.07)     | 1.72 (1.10–2.68)     | 1.53 (1.11–2.11)  |
| P                            |                  | 0.023*               | 0.018*               | 0.009*            |

*Statistically significant (\( P<0.05 \)). CI: confidence interval; GST: glutathione S-transferase
which conferred a significant increase in infertility risk (OR: 2.17; 95% CI: 1.43–3.31; P = 0.0002). Moreover, the risk was found to be further increased (approximately three-fold) in men with idiopathic oligospermia (OR: 3.12; 95% CI: 1.84–5.31; P = 0.00002) (Table 3).

**Association of triple gene combined polymorphisms with male infertility**

When the genotypes of three GST genes were combined, there were eight possible combinations. Individuals with the null genotypes for *GSTM1* and *GSTT1* and the variant *GSTP1* (Ile/Val + Val/Val) had a greatly increased risk of infertility (OR: 1.79; 95% CI: 1.07–3.00; P = 0.024). Individuals with the combination of *GSTM1*-present, *GSTT1*-null, and *GSTP1*-variant were also at higher risk of infertility (OR: 2.35; 95% CI: 1.23–4.49; P = 0.008). The other genotype combinations were not associated with significant infertility risk (Table 4).

**DISCUSSION**

In this case-control study, the *GSTP1* variant genotype (Ile/Val + Val/Val) was present at a much higher frequency in every group of infertile men than in the fertile control group. Meanwhile, the distribution of polymorphisms in the *GSTM1*/T1 genes did not demonstrate significant differences between the groups. The frequency of the *GSTM1*-null genotype ranges from 42%–60% in Europeans, 42%–54% in Asians, and 16%–36% in Africans, while for the *GSTT1*-null genotype, the reported frequencies are 13%–26% in Caucasians and 35%–52% in Asians. In Asians, the frequencies of the *GSTP1*-Ile/Ile,-Ile/Val, and -Val/Val genotypes are 52%–93%, 24%–44%, and 4%–5%, respectively. In this study, we revealed that, in fertile controls, the frequency of the *GSTM1*-null genotype was 50.9%, the frequency of the *GSTT1*-null genotype was 47.0%, and the frequencies of the *GSTP1*-Ile/Ile,-Ile/Val, and -Val/Val genotypes were 62.4%, 35.5%, and 2.1%, respectively. The distribution of the *GSTP1* genotypes in the controls was in Hardy–Weinberg equilibrium.

Spermatogenesis is an orchestrated process that is regulated by many genes present on both the autosomal and sex chromosomes. Many different mutations and polymorphisms may lead to male infertility. Implicated polymorphisms include *CYP1A*, *SOD2*, *NQO1*, *PON1–55*, *ER-α*, *ER-β*, *GSTM1*, *T1*, and *P1* gene polymorphisms. The GST system is one of the most important in protecting cells from oxidative damage; it works to inactivate endogenous unsaturated epoxides, aldehydes, hydroperoxides, and quinines in conditions of oxidative stress.

It has been suggested that polymorphisms in *GSTM1*, *GSTT1*, and *GSTP1* are associated with male infertility. In this study, we revealed that, in fertile controls, the frequency of the *GSTM1*-null genotype was 50.9%, the frequency of the *GSTT1*-null genotype was 47.0%, and the frequencies of the *GSTP1*-Ile/Ile,-Ile/Val, and -Val/Val genotypes were 62.4%, 35.5%, and 2.1%, respectively. The distribution of the *GSTP1* genotypes in the controls was in Hardy–Weinberg equilibrium.

**Table 3: Distribution of double GST genotypes among infertile males and controls**

| GSTM1 and GSTT1 | Controls (n=234) | Azoospermia (n=361) | Oligospermia (n=118) | All cases (n=479) |
|-----------------|-----------------|---------------------|---------------------|------------------|
| Both present    | 67 (28.6%)      | 94 (26.0%)          | 30 (25.4%)          | 124 (25.9%)      |
| M1 present and T1 null | 48 (20.5%)  | 78 (21.6%)          | 30 (25.4%)          | 108 (22.5%)      |
| Odds ratio (95% CI) | 1.07 (0.71–1.60) | 1.32 (0.78–2.23) | 1.27 (0.87–1.85) |                  |
| P               | 0.750           | 0.296               | 0.222               |                  |
| M1 null and T1 present | 57 (24.4%)  | 87 (24.1%)          | 19 (16.1%)          | 106 (22.1%)      |
| Odds ratio (95% CI) | 0.99 (0.67–1.45) | 0.60 (0.34–1.06) | 0.88 (0.61–1.28) |                  |
| P               | 0.943           | 0.076               | 0.506               |                  |
| Both null       | 62 (26.5%)      | 102 (28.3%)         | 39 (33.1%)          | 141 (26.5%)      |
| Odds ratio (95% CI) | 1.09 (0.76–1.58) | 1.37 (0.85–2.22) | 1.16 (0.82–1.64) |                  |
| P               | 0.639           | 0.200               | 0.414               |                  |

| GSTM1 and GSTP1 | Controls (n=234) | Azoospermia (n=361) | Oligospermia (n=118) | All cases (n=479) |
|-----------------|-----------------|---------------------|---------------------|------------------|
| M1 present and P1 (Ile/Ile) | 73 (31.2%)  | 84 (23.3%)          | 34 (28.8%)          | 118 (24.6%)      |
| M1 present and P1 (Ile/Val and Val/Val) | 42 (17.9%)  | 88 (24.4%)          | 26 (22.0%)          | 114 (23.8%)      |
| Odds ratio (95% CI) | 1.47 (0.98–2.22) | 1.29 (0.75–2.24) | 1.43 (0.96–2.12) |                  |
| P               | 0.064           | 0.360               | 0.076               |                  |
| M1 null and P1 (Ile/Ile) | 73 (31.2%)  | 107 (29.6%)         | 24 (20.3%)          | 131 (27.3%)      |
| Odds ratio (95% CI) | 0.93 (0.65–1.33) | 0.56 (0.33–0.95) | 0.83 (0.59–1.17) |                  |
| P               | 0.687           | 0.032*              | 0.286               |                  |
| M1 null and P1 (Ile/Val and Val/Val) | 46 (19.7%)  | 82 (22.7%)          | 34 (28.8%)          | 116 (24.2%)      |
| Odds ratio (95% CI) | 1.20 (0.80–1.80) | 1.65 (0.99–2.76) | 1.31 (0.89–1.92) |                  |
| P               | 0.376           | 0.053               | 0.173               |                  |

| GSTT1 and GSTP1 | Controls (n=234) | Azoospermia (n=361) | Oligospermia (n=118) | All cases (n=479) |
|-----------------|-----------------|---------------------|---------------------|------------------|
| T1 present and P1 (Ile/Ile) | 69 (29.5%)  | 97 (26.9%)          | 29 (24.6%)          | 126 (26.3%)      |
| T1 present and P1 (Ile/Val and Val/Val) | 55 (23.5%)  | 84 (23.3%)          | 20 (16.9%)          | 104 (21.7%)      |
| Odds ratio (95% CI) | 0.99 (0.67–1.46) | 0.66 (0.38–1.17) | 0.90 (0.62–1.31) |                  |
| P               | 0.947           | 0.157               | 0.590               |                  |
| T1 null and P1 (Ile/Ile) | 77 (32.9%)  | 94 (26.0%)          | 29 (24.6%)          | 123 (25.7%)      |
| Odds ratio (95% CI) | 0.72 (0.50–1.03) | 0.66 (0.40–1.10) | 0.70 (0.50–0.99) |                  |
| P               | 0.071           | 0.108               | 0.044*              |                  |
| T1 null and P1 (Ile/Val and Val/Val) | 33 (14.1%)  | 86 (23.8%)          | 40 (33.9%)          | 126 (26.3%)      |
| Odds ratio (95% CI) | 1.90 (1.23–2.96) | 3.12 (1.84–5.31) | 2.17 (1.43–3.31) |                  |
| P               | 0.004*          | <0.001*             | <0.001*             |                  |

*Statistically significant (P<0.05). CI: confidence interval; GST: glutathione S-transferase.
et al. concluded that the frequency of the GSTM1-null genotype is of great significance to idiopathic male infertility. Wu et al. revealed that the GSTT1-null genotype predisposes to excess oxidative damage to the spermatocytes of infertile males with varicocele. A similar increase in infertility risk was also reported in Iranian and Brazilian populations. In contrast, one study in the United States reported an association between the GSTT1-nonnull genotype and a reduction in sperm concentration and count. Another study, in Russian men with idiopathic infertility, suggested increased infertility with the nondeletion genotype of the GSTT1 gene. In Iran, Safarinejad et al. found that the variant genotypes of GSTP1 (Ile/Val + Val/Val) resulted in a significant decreased risk of infertility. In China, Tang et al. found that GSTP1 allelic variation showed barely any difference between the infertile and control groups. One study in Iran by Lakpour's group revealed that all individuals in both the oligoasthenoteratozoospermia and normozoospermia groups had the same GSTP1 (Ile/Ile) genotype, indicating no significant association between GSTP1 and sperm parameters. The discrepancies among these studies could be explained by factors such as different ethnic backgrounds, study populations, sample collection methods, and study sample sizes.

In a review, Safarinejad et al. suggested that the GSTM1-and GSTT1-null genotypes are associated with a strong and modest increase in the risk of male infertility, respectively, while the GSTP1 Ile/Val genotype has a protective effect. In complete contrast, our findings underrated the effect of the null genetic variants of GSTM1 and GSTT1 in modulating the risk of male infertility, and suggested, for the first time, that the GSTP1 variant genotype (Ile/Val + Val/Val) may contribute to the development of infertility. In investigating the combined effect of the GST genes, we found that GSTT1-null and GSTP1 (Ile/Val + Val/Val) have a certain degree of synergism, resulting in a greatly increased risk of infertility; this was not the case for the GSTM1-null. Besides, the presence or absence of GSTM1 had barely any effect when the three GST genes were studied together. The most likely explanation is based on the different biological mechanisms of the three different GST genes. It has been reported that GSTM1 and GSTT1 polymorphisms could cause disparities in enzyme activities, and GSTM1-null/GSTT1-null individuals have a complete absence of activity of these enzymes. However, one study in India revealed that the absence of GSTM1 activity can be compensated for by the overexpression of GSTM2. Another study reported that the induction or repression of GST T1 on the sperm surface resulted in decreased sperm motility. GSTP1, unlike the former two, did not simply affect GSH metabolism, but interacted with Jun kinase to inhibit apoptosis and promote cellular proliferation. By stratification in the infertility group, we demonstrated that individuals with infertility-risk genotypes were more likely to have oligospermia than azoospermia. This is consistent with a study conducted by Tang et al. We speculate that protein defects in the GST family alone might be insufficient to cause azoospermia. This is because the major role of the enzymes encoded by GSTs is in the mitigation of reactive oxygen species; therefore, these enzymes are more likely to affect the quantity, survival, and/or activity of sperm that have been produced.

We should acknowledge several limitations of this case-control study. First, the relatively small sample size in the oligospermia group and in the controls would substantially decrease the statistical power to explore real associations. Second, this study did not contain complete information about family history of infertility. Third, genetic association studies are prone to population-specific genotype effects. Finally, we did not address gene-gene or gene-environment interactions.

CONCLUSION

In Sichuan, southwest China, males with the variant genotypes of GSTP1 (Ile/Val or Val/Val) have an increased risk of infertility.
In addition, we have underrated the significance of the effect of GSTM1 and/or GSTTI (especially GSTM1) in modulating the risk of male infertility. Further studies should be conducted on a larger scale to confirm our results, and functional studies undertaken to explore the effect of GST variants.

**AUTHOR CONTRIBUTIONS**

DKX and HHC designed the study, acquired the data, interpreted and analyzed the data, and drafted and revised the manuscript. SHZ and JHZ collected some of the clinical data and acquired some of the data. All authors read and approved the final manuscript.

**COMPETING INTERESTS**

The authors declare no competing interests.

**REFERENCES**

1. Aston KL, Krausz C, Laface I, Ruiz-Castan E, Carroll DT. Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent. Hum Reprod 2010; 25: 1383–97.

2. Bovin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007; 22: 1506–12.

3. Safarinejad MR. Infertility among couples in a population-based study in Iran: prevalence and associated risk factors. Int J Androl 2008; 31: 303–14.

4. Ferlin A. New genetic markers for male fertility. Asian J Androl 2012; 14: 807–8.

5. Pasqualotto FF, Pasqualotto EB, Sobreiro BP, Hallak J, Medeiros F, et al. Clinical diagnosis in men undergoing infertility investigation in a university hospital. Urol Int 2006; 76: 122–5.

6. Comhaire FH, Mahmoud AM, Schoonjans F. Sperm quality, birth rates and the environment in Flanders (Belgium). Reprod Toxicol 2007; 23: 133–7.

7. Baker MA, Atkin RJ. Proteomic insights into spermatozoa: critiques, comments and concerns. Expert Rev Proteomics 2009; 6: 691–705.

8. Ketterer B. A bird’s eye view of the glutathione transferase field. Chem Biol Interact 2001; 138: 27–42.

9. Dusínska M, Ficek A, Horská A, Ruslová K, Petrovská H, et al. Glutathione S-transferase polymorphisms influence the level of oxidative DNA damage and antioxidant protection in humans. Mutat Res Rev 2001; 482: 47–55.

10. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transfers. Annu Rev Pharmacol Toxicol 2005; 45: 51–88.

11. Jiang S, Yu L, Cheng J, Leng S, Dai Y, et al. Genomic damages in peripheral blood lymphocytes and association with polymorphisms of three glutathione S-transferases in workers exposed to formaldehyde. Mutat Res Rev 2010; 695: 9–15.

12. Bohaneck Grabar P, Logar D, Rismc M, Rozman B, Dolzan V. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 229–36.

13. Trumula Vani G, Mukesh N, Tirumala Vani G, Siva Prasad B, Rama Devi P, et al. Role of glutathione S-transferase Mu-1 (GSTM1) polymorphism in oligospermic infertile males. Andrologia 2010; 42: 213–7.

14. Safarinejad MR, Shafiei N, Safarinejad S. Association of polymorphisms in the estrogen receptors alpha, and beta (ESR1, ESR2) with the occurrence of male infertility and semen parameters. J Steroid Biochem Mol Biol 2010; 122: 193–203.

15. Aydos SE, Taspinar M, Sungurolu A, Aydos K. Association of CYP1A1 and glutathione S-transferase polymorphisms with male factor infertility. Fertil Steril 2009; 92: 541–7.

16. Ichikawa M, Nakahama K, Okubo K, Soda T, Ogawa O, et al. Genetic polymorphisms in glutathione S-transferase T1 affect the surgical outcome of varicocelectomies in infertile patients. Asian J Androl 2009; 11: 333–41.

17. Volk M, Jaklic H, Zorn B, Peterlin B. Association between male infertility and genetic variability at the PON1/2 and GSTM1/T1 gene loci. Reprod Biomed Online 2011; 23: 105–10.

18. Su MT, Chen CH, Kou PH, Hu CC, Lee IW, et al. Polymorphisms of estrogen-related genes jointly confer susceptibility to human spermaticogenetic defect. Fertil Steril 2010; 93: 141–9.

19. Sharma R, Yang Y, Sharma A, Awasthi S, Awasthi VC. Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid Redox Signal 2004; 6: 289–300.

20. Temelken K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14: 243–58.

21. Aydemin B, Onaran I, Kirzler AR, Alici B, Akylolu MC. Increased oxidative damage of sperm and seminal plasma in men with idiopathic infertility is higher in patients with glutathione S-transferase Mu-1 null genotype. Asian J Androl 2007; 9: 108–15.

22. Lakpour N, Mirfeizollahi A, Farivar S, Akhondi MM, Hashemi SB, et al. The association of seminal plasma antioxidant levels and sperm chromatin status with genetic variants of GSTM1 and GSTP1 (Ile105Val and Ala114Val) in infertile men with oligoasthenoteratozoospermia. Dis Markers 2013; 34: 205–10.

23. Finotti AC, Costa E Silva RC, Bordin BM, Silva CT, Moura KK. Glutathione S-transferase M1 and T1 polymorphism in men with idiopathic infertility. Genet Mol Res 2009; 8: 1093–8.

24. Polonikov AV, Yarosh SL, Kohkteno EV, Starodubova NI, Pakhomov SP, et al. The functional genotype of glutathione S-transferase T1 gene is strongly associated with increased risk of idiopathic infertility in Russian men. Fertil Steril 2010; 94: 1144–7.

25. Safarinejad MR, Dadkhah F, Ali Asgari M, Hosseini SY, Kolahi AA, Iran-Pour E. Glutathione S-transferase polymorphisms (GSTM1, GSTTI, GSTP1) and male factor infertility risk: a pooled analysis of studies. Urol J 2012; 9: 541–8.

26. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006; 100: 330–7.

27. Bhattacharjee P, Patel S, Baranjee M, Patra D, Baranjee P, et al. Functional compensation of glutathione S-transferase M1 null by another GST superfamily member, GSTM2. Sci Rep 2013; 3: 2704.

28. De Luca A, Federici L, De Canio M, Stella L, Caccuri AM. New insights into the mechanism of JNK1 inhibition by glutathione transferase P1-1. Biochemistry 2012; 51: 7304–12.

29. Tekelioglu Z, Gokalp G, Yilmaz A, Dursun B, Aksoy M, et al. Genetic polymorphisms in glutathione S-transferase M1, T1, and P1 and the assessment of oxidative damage in infertile men with varicoceles from Northwestern China. J Androl 2012; 33: 257–63.